title: Improvement effect of resistant maltodextrin in humans with metabolic syndrome by continuous administration.
abstract: Resistant maltodextrin (RMD) is a soluble dietary fiber ingredient whose physiological functions are well recognized in Foods for Specified Health Use (FOSHU) for maintaining healthy intestinal regularity, blood glucose levels, and serum lipids. However, its efficacy on combined health risks--metabolic syndrome--was not studied yet. In this study the efficacy of RMD on humans with metabolic syndrome was investigated. A randomized double-blind placebo-controlled parallel-group trial was conducted. Thirty subjects with metabolic syndrome were randomly allocated into 2 groups and took either tea containing 9 g of RMD (treatment group) or placebo tea at three mealtimes daily for 12 wk. Blood was collected and body fat was scanned periodically. In the RMD treatment group, waist circumference, visceral fat area, fasting blood glucose, HOMA-R and serum triacylglycerol (TG) were significantly decreased compared to baseline, and significant time-by-treatment interaction was observed for waist circumference, visceral fat area, HOMA-R and serum TG (p=0.044, p=0.012, p=0.032, and p=0.049, respectively). The change ratio of visceral fat area showed negative statistical correlation with the baseline value (p=0.033), suggesting that efficacy of RMD was emphasized in the subjects having a larger visceral fat area. After the 12-wk RMD treatment, the total number of metabolic syndrome risk factors decreased to 20 from 32 with 2 subjects having no risks, while that of the placebo group decreased to 25 from 32. These findings suggest that continuous ingestion of RMD may improve the risk factors of metabolic syndrome by reducing visceral fat and improving glucose and lipid metabolism.
authors: Matsutani Chemical Industry Co., Ltd., Hyogo, Japan.
authors: Chieko
authors: C
authors: Hashizume
authors: Yuka
authors: Y
authors: Kishimoto
authors: Sumiko
authors: S
authors: Kanahori
authors: Takushi
authors: T
authors: Yamamoto
authors: Kazuhiro
authors: K
authors: Okuma
authors: Kunio
authors: K
authors: Yamamoto
mesh_terms: D000368:Aged; D044466:Asian People; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007328:Insulin / Q000097:blood; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy; D011134:Polysaccharides / Q000008:administration & dosage*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D011134:Polysaccharides; D014280:Triglycerides; C008315:maltodextrin; D002784:Cholesterol